Motion Equity Partners has invested in Groupe Axience, a leading French veterinary laboratory, with the aim of supporting its growth and expansion in the European market.

Target Information

Motion Equity Partners has announced its investment in Groupe Axience, a leading French laboratory specializing in the development and commercialization of veterinary products. Founded in 2001, Groupe Axience focuses on pharmaceutical and over-the-counter (OTC) products primarily for companion animals, operating under two key brands: Axience and Anidev.

The company's comprehensive offerings in its historical segments cater to the varied needs of veterinarians. Axience has established itself as a notable player in the veterinary sector, particularly recognized for its analgesics and anesthetics, where it holds the top market position. Additionally, it offers a leading range of antibiotics and hygiene solutions aimed at preventing and controlling infections in veterinary clinics. Anidev complements this portfolio by providing OTC products that support Axience's offerings.

Industry Overview

The veterinary health market in France is characterized by dynamic growth driven by underlying trends such as the increasing humanization of pets. This shift reflects a broader global tendency where pet owners are increasingly